Uchimoto, T.; Komura, K.; Fukuokaya, W.; Kimura, T.; Takahashi, K.; Nishimura, K.; Nakamori, K.; Fujiwara, Y.; Matsunaga, T.; Tsutsumi, T.;
et al. Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers 2021, 13, 526.
https://doi.org/10.3390/cancers13030526
AMA Style
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T,
et al. Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers. 2021; 13(3):526.
https://doi.org/10.3390/cancers13030526
Chicago/Turabian Style
Uchimoto, Taizo, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, Takeshi Tsutsumi,
and et al. 2021. "Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer" Cancers 13, no. 3: 526.
https://doi.org/10.3390/cancers13030526
APA Style
Uchimoto, T., Komura, K., Fukuokaya, W., Kimura, T., Takahashi, K., Nishimura, K., Nakamori, K., Fujiwara, Y., Matsunaga, T., Tsutsumi, T., Tsujino, T., Maenosono, R., Yoshikawa, Y., Taniguchi, K., Tanaka, T., Uehara, H., Ibuki, N., Hirano, H., Nomi, H.,
... Azuma, H.
(2021). Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 13(3), 526.
https://doi.org/10.3390/cancers13030526
